Adjusting Your Pitching Strategy
Source: Life Science Leader
Markus Warmuth, M.D., CEO, Monte Rosa Therapeutics, discusses the importance of adjusting strategy when pitching in a cash-strapped environment. This transitions into a conversation on how we might have to readjust again once we are able to get back to pitching in person, with Keith Vendola, M.D., CSO and head of strategy at Rezolute. Josh Brumm, CEO of Dyne Therapeutics, adds to the conversation that was part of a longer executive virtual roundtable (EVR) titled, Pitching And Fundraising In The New Norm (view full video here).
This website uses cookies to ensure you get the best experience on our website. Learn more